en · de · es
sr9009-notes.peptides1004.com › Guide › Mechanism And Preclinical Findings — Beginner to Advanced

Mechanism And Preclinical Findings — Beginner to Advanced

By Editorial Desk · published 2026-04-06 · last reviewed 2026-05-04 · Guide

LC-MS is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.

Updated 2026-05-04. Numbers and descriptions here follow the published literature rather than marketing material.

Mechanism and Preclinical Findings

Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

Identity, Handling, and Regulation

In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.

Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.

Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.

Sr9009 at a glance

PropertyValueNotes
Chemical classSynthetic REV-ERB agonistSmall molecule; not a steroid or peptide.
Primary targetsNR1D1 and NR1D2Also known as REV-ERBα and REV-ERBβ.
Studied routesIntraperitoneal in rodentsOral bioavailability in humans is not established.
Human approvalNo approved therapeutic indicationNo recognized clinical use.
Key uncertaintyHuman physiological effectsPreclinical findings may not translate.

Background and Pharmacological Mechanism

SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.

Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.

SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.

Related pages on this site

Analytical Detection and Regulatory Status

Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.

Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.

Notes from published material

In India, Ayurvedic medicine has quite complex formulas with 30 or more ingredients, including a sizable number of ingredients that have undergone "alchemical processing", chosen to balance dosha. In Ladakh, Lahul-Spiti, and Tibet, the Tibetan Medical System is prevalent, also called the "Amichi Medical System". Over 337 species of medicinal plants have been documented by C.P. Kala. Those are used by Amchis, the practitioners of this medical system. The Indian book, Vedas, mentions treatment of diseases with plants.

=== Hotels === The Regent Palace Hotel, Glasshouse Street, London was operated by Strand Hotels Limited, a subsidiary of J. Lyons and Company and opened on 16 May 1915. Strand Hotels also operated the Cumberland Hotel (Marble Arch, London), Kingsley Hotel, Park Court Hotel, Windsor Hotel, White's Hotel and the Strand Palace Hotel after the inception of Strand Hotels Limited. The last London hotel that they operated until the demise of the group in the mid-1970s was the Tower Hotel situated by Tower Bridge in London.

=== Biology === DMSO is used in the polymerase chain reaction (PCR) to inhibit secondary structures in the DNA template or the DNA primers. It is added to the PCR mix before reacting, where it interferes with the self-complementarity of the DNA, minimizing interfering reactions. DMSO in a PCR is applicable for supercoiled plasmids (to relax before amplification) or DNA templates with high GC-content (to decrease thermostability). For example, 10% final concentration of DMSO in the PCR mixture with Phusion decreases primer annealing temperature (i.e., primer melting temperature) by 5.5–6.0 °C (9.9–10.8 °F). It is well known as a reversible cell cycle arrester at phase G1 of human lymphoid cells. DMSO may also be used as a cryoprotectant, added to cell media to reduce ice formation and thereby prevent cell death during the freezing process. Approximately 10% may be used with a slow-freeze method, and the cells may be frozen at −80 °C (−112 °F) or stored in liquid nitrogen safely. In cell culture, DMSO is used to induce differentiation of P19 embryonic carcinoma cells into cardiomyocytes and skeletal muscle cells.

Sources: en.wikipedia.org

Background from the literature

=== Other applications === Easton-Bell Sports, Inc. have been in partnership with Zyvex Performance Materials, using CNT technology in a number of their bicycle components – including flat and riser handlebars, cranks, forks, seatposts, stems and aero bars. Amroy Europe Oy manufactures Hybtonite carbon nano-epoxy resins where carbon nanotubes have been chemically activated to bond to epoxy, resulting in a composite material that is 20% to 30% stronger than other composite materials. It has been used for wind turbines, marine paints and a variety of sports gear such as skis, ice hockey sticks, baseball bats, hunting arrows, and surfboards. Surrey NanoSystems synthesizes carbon nanotubes to create vantablack ultra-absorptive black paint. "Gecko tape" (also called "nano tape") is often commercially sold as double-sided adhesive tape. It can be used to hang lightweight items such as pictures and decorative items on smooth walls without punching holes in the wall. The carbon nanotube arrays comprising the synthetic setae leave no residue after removal and can stay sticky in extreme temperatures. Tips for atomic force microscope probes. One proposed use of carbon nanotubes is in paper batteries, developed in 2007 by researchers at Rensselaer Polytechnic Institute. Another highly speculative proposed use in the field of space technologies is to produce high-tensile carbon cables required by a space elevator.

Russian forces captured the village of Tymofiivka in Donetsk Oblast. Russia launched a massive drone attack on Kyiv, with Ukrainian forces claiming to have intercepted 40 drones. Russian forces claimed to have intercepted a Neptune-MD missile and 19 drones over Belgorod, Bryansk, Kursk, Kaluga, and Rostov Oblasts as well as in Crimea. The acting governor of Kursk, Alexei Smirnov, said that an “unidentified facility” caught fire after midnight. Ukraine claimed it was a “storage facility for weapons and military equipment”. In Belgorod, commercial and residential properties caught fire. No casualties were reported in the attacks. The Belgorod governor also claimed Ukrainian forces fired six cluster shells at buildings. The Freedom of Russia Legion announced its withdrawal from the Irpin Declaration, but said that it would continue to fight Kremlin forces. A Russian Mi-8 helicopter was shot down over occupied Donetsk, speculated to be either by a Ukrainian FPV drone or by Russian fire. Ukraine received its first F-16s. Austrian military analyst Col. Markus Reisner, citing a recent military study, estimated that Russian forces had lost between 500,000 and 750,000 soldiers killed and wounded in action, with "perhaps" 100,000 to 150,000 Russian soldiers killed. He also said that Ukraine had "suffered very heavy losses".

BIOCEV (Biotechnology and Biomedicine Centre of the Academy of Sciences and Charles University) is a joint research institute located in Vestec, Czech Republic. Established in 2015, it is operated by six institutes of the Czech Academy of Sciences (CAS) and two faculties of Charles University (Faculty of Science, Charles University and First Faculty of Medicine, Charles University). The center maintains collaborative ties with other institutions in the STAR cluster.

Sources: en.wikipedia.org

Reference notes

"Cellulose" . Encyclopædia Britannica. Vol. 5 (11th ed.). 1911. Structure and morphology of cellulose by Serge Pérez and William Mackie, CERMAV-CNRS Cellulose, by Martin Chaplin, London South Bank University Clear description of a cellulose assay method at the Cotton Fiber Biosciences unit of the USDA. Cellulose films could provide flapping wings and cheap artificial muscles for robots – TechnologyReview.com

Alkynylstannanes, the most reactive of stannanes, have also been used in Stille couplings. They are not usually needed as terminal alkynes can couple directly to palladium catalysts through their C-H bond via Sonogashira coupling. Allylstannanes have been reported to have worked, yet difficulties arise, like with allylic halides, with the difficulty in control regioselectivity for α and γ addition. Distannane and acyl stannane reagents have also been used in Stille couplings.

The 4n+2 chain of uranium-238 is called the "uranium series" or "radium series", the latter from the first member known when it was named, radium-226. The series terminates with lead-206, 8 alpha decays and 6 beta decays from uranium. The total energy released from uranium-238 to lead-206, including the energy lost to neutrinos, is 51.69 MeV; from californium-250, 68.28 MeV.

Endocrine signals are called hormones. Hormones are produced by endocrine cells and they travel through the blood to reach all parts of the body. Specificity of signaling can be controlled if only some cells can respond to a particular hormone. Endocrine signaling involves the release of hormones by internal glands of an organism directly into the circulatory system, regulating distant target organs. In vertebrates, the hypothalamus is the neural control center for all endocrine systems. In humans, the major endocrine glands are the thyroid gland and the adrenal glands. The study of the endocrine system and its disorders is known as endocrinology.

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.

How does SR9009 differ from typical receptor agonists?

REV-ERB receptors generally repress transcription when bound by natural heme. SR9009 is described as an agonist that enhances this repressive activity. The result is altered expression of clock and metabolic genes.

Has SR9009 been tested in humans?

Published controlled human trials are lacking. Some sources cite limited or unofficial reports, but these do not establish safety or efficacy. Claims about human performance effects remain unverified.

How is SR9009 usually analyzed?

Liquid chromatography–mass spectrometry is common for identity and purity checks. High-performance liquid chromatography with ultraviolet detection can also be used. Both methods require a suitable reference standard.

Network